SCHEMBL12420743

SCHEMBL12420743

O=C(O)c1ccnc(OCCc2ccccc2F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 5/20 0.55
KDM5B Q9UGL1 5/20 0.55
KDM4C Q9H3R0 6/20 0.51
KDM4A O75164 4/20 0.51
KDM4E B2RXH2 2/20 0.44
KDM6B O15054 2/20 0.44
KDM5C P41229 2/20 0.44
KDM2A Q9Y2K7 2/20 0.44
KDM3A Q9Y4C1 2/20 0.44
AKR1C3 P42330 1/20 0.44
NR3C2 P08235 1/20 0.43
KDM1A O60341 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.41
LPAR1 Q92633 1/20 0.40
LPAR5 Q9H1C0 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
MAOB P27338 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
RARA P10276 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12420849 0.86 KDM5A (0.62) KDM5AKDM5BKDM4CKDM4AKDM4E
SCHEMBL2195411 0.84 KDM4C (0.55) KDM5AKDM5BKDM4CKDM4AKDM4E
SCHEMBL12420863 0.84 NR3C2 (0.46) KDM5AKDM5BKDM4CKDM4AKDM4E
SCHEMBL12420736 0.82 KDM5A (0.52) KDM5AKDM5BKDM4CKDM4AKDM4E
SCHEMBL12420861 0.79 KDM5A (0.51) KDM5AKDM5BKDM4CKDM4AKDM4E
SCHEMBL12420751 0.78 KDM5A (0.57) KDM5AKDM5BKDM4CNR3C2MRGPRX4
SCHEMBL16453501 0.78 TAAR1 (0.40) KDM4ENR3C2MAOBSIRT2MAPT
SCHEMBL31729821 0.76 TP53 (0.55) KDM5AKDM5BKDM4CRARB
SCHEMBL16453515 0.76 NR3C2 (0.41) KDM4ENR3C2MAOB
SCHEMBL2546283 0.75 KDM4C (0.50) KDM5AKDM5BKDM4CKDM4AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-07-14 US disclosed
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172230-A1 UREA COMPOUND OR SALT THEREOF FAAH, FAAH2, UTS2R KDM5A 301/4885KDM5B 304/4885KDM4C 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.